Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

Xiaosheng Wu, Mary Stenson, Jithma Abeykoon, Kevin Nowakowski, Lianwen Zhang, Joshua Lawson, Linda Wellik, Ying Li, Jordan Krull, Kerstin Wenzl, Anne J Novak, Stephen Maxted Ansell, Gail A. Bishop, Daniel D Billadeau, Kah Whye Peng, Francis Giles, Daniel M. Schmitt, Thomas Elmer Witzig

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Targeting the B-cell receptor and phosphatidylinositol 3-kinase/mTOR signaling pathways has shown meaningful, but incomplete, antitumor activity in lymphoma. Glycogen synthase kinase 3 (GSK3) α and β are 2 homologous and functionally overlapping serine/threonine kinases that phosphorylate multiple protein substrates in several key signaling pathways. To date, no agent targeting GSK3 has been approved for lymphoma therapy. We show that lymphoma cells abundantly express GSK3α and GSK3β compared with normal B and T lymphocytes at the messenger RNA and protein levels. Utilizing a new GSK3 inhibitor 9-ING-41 and by genetic deletion of GSK3α and GSK3β genes using CRISPR/CAS9 knockout, GSK3 was demonstrated to be functionally important to lymphoma cell growth and proliferation. GSK3b binds to centrosomes and microtubules, and lymphoma cells treated with 9-ING-41 become arrested in mitotic prophase, supporting the notion that GSK3β is necessary for the progression of mitosis. By analyzing recently published RNA sequencing data on 234 diffuse large B-cell lymphoma patients, we found that higher expression of GSK3α or GSK3β correlates well with shorter overall survival. These data provide rationale for testing GSK3 inhibitors in lymphoma patient trials.

Original languageEnglish (US)
Pages (from-to)363-373
Number of pages11
JournalBlood
Volume134
Issue number4
DOIs
StatePublished - Jul 25 2019

Fingerprint

Glycogen Synthase Kinase 3
Lymphoma
Therapeutics
B-Lymphocytes
Clustered Regularly Interspaced Short Palindromic Repeats
Cells
Phosphatidylinositol 3-Kinase
RNA Sequence Analysis
Prophase
Centrosome
T-cells
Lymphoma, Large B-Cell, Diffuse
Protein-Serine-Threonine Kinases
Cell proliferation
Cell growth
Mitosis
Microtubules
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Wu, X., Stenson, M., Abeykoon, J., Nowakowski, K., Zhang, L., Lawson, J., ... Witzig, T. E. (2019). Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood, 134(4), 363-373. https://doi.org/10.1182/blood.2018874560

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. / Wu, Xiaosheng; Stenson, Mary; Abeykoon, Jithma; Nowakowski, Kevin; Zhang, Lianwen; Lawson, Joshua; Wellik, Linda; Li, Ying; Krull, Jordan; Wenzl, Kerstin; Novak, Anne J; Ansell, Stephen Maxted; Bishop, Gail A.; Billadeau, Daniel D; Peng, Kah Whye; Giles, Francis; Schmitt, Daniel M.; Witzig, Thomas Elmer.

In: Blood, Vol. 134, No. 4, 25.07.2019, p. 363-373.

Research output: Contribution to journalArticle

Wu, X, Stenson, M, Abeykoon, J, Nowakowski, K, Zhang, L, Lawson, J, Wellik, L, Li, Y, Krull, J, Wenzl, K, Novak, AJ, Ansell, SM, Bishop, GA, Billadeau, DD, Peng, KW, Giles, F, Schmitt, DM & Witzig, TE 2019, 'Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma', Blood, vol. 134, no. 4, pp. 363-373. https://doi.org/10.1182/blood.2018874560
Wu X, Stenson M, Abeykoon J, Nowakowski K, Zhang L, Lawson J et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373. https://doi.org/10.1182/blood.2018874560
Wu, Xiaosheng ; Stenson, Mary ; Abeykoon, Jithma ; Nowakowski, Kevin ; Zhang, Lianwen ; Lawson, Joshua ; Wellik, Linda ; Li, Ying ; Krull, Jordan ; Wenzl, Kerstin ; Novak, Anne J ; Ansell, Stephen Maxted ; Bishop, Gail A. ; Billadeau, Daniel D ; Peng, Kah Whye ; Giles, Francis ; Schmitt, Daniel M. ; Witzig, Thomas Elmer. / Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. In: Blood. 2019 ; Vol. 134, No. 4. pp. 363-373.
@article{a17837d4a88e4a6cba8cd79c775e36e4,
title = "Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma",
abstract = "Targeting the B-cell receptor and phosphatidylinositol 3-kinase/mTOR signaling pathways has shown meaningful, but incomplete, antitumor activity in lymphoma. Glycogen synthase kinase 3 (GSK3) α and β are 2 homologous and functionally overlapping serine/threonine kinases that phosphorylate multiple protein substrates in several key signaling pathways. To date, no agent targeting GSK3 has been approved for lymphoma therapy. We show that lymphoma cells abundantly express GSK3α and GSK3β compared with normal B and T lymphocytes at the messenger RNA and protein levels. Utilizing a new GSK3 inhibitor 9-ING-41 and by genetic deletion of GSK3α and GSK3β genes using CRISPR/CAS9 knockout, GSK3 was demonstrated to be functionally important to lymphoma cell growth and proliferation. GSK3b binds to centrosomes and microtubules, and lymphoma cells treated with 9-ING-41 become arrested in mitotic prophase, supporting the notion that GSK3β is necessary for the progression of mitosis. By analyzing recently published RNA sequencing data on 234 diffuse large B-cell lymphoma patients, we found that higher expression of GSK3α or GSK3β correlates well with shorter overall survival. These data provide rationale for testing GSK3 inhibitors in lymphoma patient trials.",
author = "Xiaosheng Wu and Mary Stenson and Jithma Abeykoon and Kevin Nowakowski and Lianwen Zhang and Joshua Lawson and Linda Wellik and Ying Li and Jordan Krull and Kerstin Wenzl and Novak, {Anne J} and Ansell, {Stephen Maxted} and Bishop, {Gail A.} and Billadeau, {Daniel D} and Peng, {Kah Whye} and Francis Giles and Schmitt, {Daniel M.} and Witzig, {Thomas Elmer}",
year = "2019",
month = "7",
day = "25",
doi = "10.1182/blood.2018874560",
language = "English (US)",
volume = "134",
pages = "363--373",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

AU - Wu, Xiaosheng

AU - Stenson, Mary

AU - Abeykoon, Jithma

AU - Nowakowski, Kevin

AU - Zhang, Lianwen

AU - Lawson, Joshua

AU - Wellik, Linda

AU - Li, Ying

AU - Krull, Jordan

AU - Wenzl, Kerstin

AU - Novak, Anne J

AU - Ansell, Stephen Maxted

AU - Bishop, Gail A.

AU - Billadeau, Daniel D

AU - Peng, Kah Whye

AU - Giles, Francis

AU - Schmitt, Daniel M.

AU - Witzig, Thomas Elmer

PY - 2019/7/25

Y1 - 2019/7/25

N2 - Targeting the B-cell receptor and phosphatidylinositol 3-kinase/mTOR signaling pathways has shown meaningful, but incomplete, antitumor activity in lymphoma. Glycogen synthase kinase 3 (GSK3) α and β are 2 homologous and functionally overlapping serine/threonine kinases that phosphorylate multiple protein substrates in several key signaling pathways. To date, no agent targeting GSK3 has been approved for lymphoma therapy. We show that lymphoma cells abundantly express GSK3α and GSK3β compared with normal B and T lymphocytes at the messenger RNA and protein levels. Utilizing a new GSK3 inhibitor 9-ING-41 and by genetic deletion of GSK3α and GSK3β genes using CRISPR/CAS9 knockout, GSK3 was demonstrated to be functionally important to lymphoma cell growth and proliferation. GSK3b binds to centrosomes and microtubules, and lymphoma cells treated with 9-ING-41 become arrested in mitotic prophase, supporting the notion that GSK3β is necessary for the progression of mitosis. By analyzing recently published RNA sequencing data on 234 diffuse large B-cell lymphoma patients, we found that higher expression of GSK3α or GSK3β correlates well with shorter overall survival. These data provide rationale for testing GSK3 inhibitors in lymphoma patient trials.

AB - Targeting the B-cell receptor and phosphatidylinositol 3-kinase/mTOR signaling pathways has shown meaningful, but incomplete, antitumor activity in lymphoma. Glycogen synthase kinase 3 (GSK3) α and β are 2 homologous and functionally overlapping serine/threonine kinases that phosphorylate multiple protein substrates in several key signaling pathways. To date, no agent targeting GSK3 has been approved for lymphoma therapy. We show that lymphoma cells abundantly express GSK3α and GSK3β compared with normal B and T lymphocytes at the messenger RNA and protein levels. Utilizing a new GSK3 inhibitor 9-ING-41 and by genetic deletion of GSK3α and GSK3β genes using CRISPR/CAS9 knockout, GSK3 was demonstrated to be functionally important to lymphoma cell growth and proliferation. GSK3b binds to centrosomes and microtubules, and lymphoma cells treated with 9-ING-41 become arrested in mitotic prophase, supporting the notion that GSK3β is necessary for the progression of mitosis. By analyzing recently published RNA sequencing data on 234 diffuse large B-cell lymphoma patients, we found that higher expression of GSK3α or GSK3β correlates well with shorter overall survival. These data provide rationale for testing GSK3 inhibitors in lymphoma patient trials.

UR - http://www.scopus.com/inward/record.url?scp=85070655611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070655611&partnerID=8YFLogxK

U2 - 10.1182/blood.2018874560

DO - 10.1182/blood.2018874560

M3 - Article

C2 - 31101621

AN - SCOPUS:85070655611

VL - 134

SP - 363

EP - 373

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -